Niagen Bioscience Inc (NASDAQ:NAGE) does about 917.99K shares in volume on a normal day but saw 1758757 shares change hands in the recent trading day. The company now has a market cap of 1.01B USD. Its current market price is $12.81, marking a decrease of -11.10% compared to the previous close of $14.41. The 52 week high reached by this stock is $14.69 whilst the lowest price level in 52 weeks is $2.40.
Niagen Bioscience Inc (NAGE) has a 20-day trading average at $13.42 and the current price is -12.80% off the 52-week high compared with 432.64% distance from its 52-week low. The 50-day simple moving average of the closing price is $10.88 and its 200-day simple moving average is $7.00. If we look at the stock’s price movements over the week, volatility stands at 7.61%, which decreases to 5.90% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 51.01 to suggest the stock is neutral.
The consensus objective for the share price is $14.90, suggesting that the stock has a potential upside of 14.03% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 27, 2025 when Canaccord Genuity initiated the stock to “Buy” and issued a price target of $13. B. Riley Securities downgraded its price target at $6-$2.40.
The current price level is -4.55%, 17.76%, and 83.04% away from its SMA20, SMA50, and SMA200 respectively, with the NAGE price moving below the 50-day SMA on current market day. Niagen Bioscience Inc (NAGE) stock is down -9.34% over the week and 18.39% over the past month. Its price is 383.40% year-to-date and 141.47% over the past year.
To reach the target analysts have set, the stock logically needs to grow 14.03 percent from here.
Outstanding shares total 78.43M with insiders holding 34.44% of the shares and institutional holders owning 33.09% of the company’s common stock. The company has a return on investment of 24.35% and return on equity of 33.47%. The price to earnings ratio (P/E ratio) amounts to 74.17 while the forward price to earnings ratio is 53.47. The beta has a value of 2.14. Price to book ratio is 18.15 and price to sales ratio is 9.35.
